| Accelerating Digital Transformation in Healthcare and Biopharma
| Collaborating to Develop Data-Driven, Next-Generation Technologies
JNPMEDI (CEO Kwunho Jeong), an AI-driven clinical trial consulting firm, announced on the 5th that it has signed a Memorandum of Understanding (MOU) with medical AI specialist Open Research (CEO Ildoo Kim) to jointly develop AI-based medical information intelligence technologies. The agreement aims to enhance information utilization across the healthcare and biopharma industries and to explore long-term innovation opportunities by combining the technological strengths of both companies.
Through this MOU, the two companies will assess the feasibility of jointly developing AI technologies for summarizing, interpreting, and structuring medical and clinical data into actionable knowledge. They will also work together to explore real-world application strategies for deploying these technologies in healthcare and biopharma settings.
Key areas of collaboration include:
- Joint development and feasibility review of AI-based medical data summarization and interpretation technologies
- Identification of use cases related to the structuring, interpretation, and knowledge modeling of medical and clinical data
- Enhancing research efficiency and synergy by sharing technical resources, research outputs, and datasets
- Establishing a foundation for collaborative R&D initiatives aimed at advancing digital transformation across the healthcare and biopharma sectors
Youngyong Park, CTO of JNPMEDI, stated, “AI-driven medical data technologies are rapidly evolving beyond simple information processing and increasingly supporting real clinical and medical decision-making. This MOU marks an important starting point in advancing medical information intelligence, and through this collaboration, we look forward to driving innovation in digital healthcare.”
Open Research CEO Ildoo Kim added, “By combining JNPMEDI’s digital clinical trial expertise with our medical AI capabilities, we can create innovative, data-driven models for the industry. Through long-term cooperation, we aim to present a new paradigm for the healthcare and biopharma sectors.”
Moving forward, the two companies will further define joint research initiatives, expand the practical utility of medical data, and continue R&D efforts to implement AI-based technologies in real-world environments.
| Accelerating Digital Transformation in Healthcare and Biopharma
| Collaborating to Develop Data-Driven, Next-Generation Technologies
JNPMEDI (CEO Kwunho Jeong), an AI-driven clinical trial consulting firm, announced on the 5th that it has signed a Memorandum of Understanding (MOU) with medical AI specialist Open Research (CEO Ildoo Kim) to jointly develop AI-based medical information intelligence technologies. The agreement aims to enhance information utilization across the healthcare and biopharma industries and to explore long-term innovation opportunities by combining the technological strengths of both companies.
Through this MOU, the two companies will assess the feasibility of jointly developing AI technologies for summarizing, interpreting, and structuring medical and clinical data into actionable knowledge. They will also work together to explore real-world application strategies for deploying these technologies in healthcare and biopharma settings.
Key areas of collaboration include:
Youngyong Park, CTO of JNPMEDI, stated, “AI-driven medical data technologies are rapidly evolving beyond simple information processing and increasingly supporting real clinical and medical decision-making. This MOU marks an important starting point in advancing medical information intelligence, and through this collaboration, we look forward to driving innovation in digital healthcare.”
Open Research CEO Ildoo Kim added, “By combining JNPMEDI’s digital clinical trial expertise with our medical AI capabilities, we can create innovative, data-driven models for the industry. Through long-term cooperation, we aim to present a new paradigm for the healthcare and biopharma sectors.”
Moving forward, the two companies will further define joint research initiatives, expand the practical utility of medical data, and continue R&D efforts to implement AI-based technologies in real-world environments.